CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
ARN-509 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02772588
NCT02772588Phase 2Completed
CompareCT.gov

ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study

Memorial Sloan Kettering Cancer Center·interventional·Posted May 13, 2016·Updated Apr 13, 2026

In Brief

A Phase 2 clinical trial evaluating ARN-509, Abiraterone, and 2 other interventions for Prostate Cancer. Completed, enrolled 64 participants across 11 sites.

Detailed Summary

The purpose of this study is to determine whether anti-testosterone medications, when administered before, during, and after high-dose, precision radiation, will be effective in preventing the prostate cancer from returning.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsJanssen Pharmaceuticals, Weill Medical College of Cornell University, University of Michigan

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 13, 2016
Enrollment StartMay 12, 2016
Primary CompletionJan 22, 2026
TodayJul 2, 2026
Enrollment to primary: 9.7 yearsPosted 10.1 years ago

Interventions

ARN-509drug

Abirateronedrug

Leuprolidedrug

stereotactic, ultra-fractionated radiotherapyradiation